indiana fishing license
phmacao casino super ace live casino&slots
Marvel Rivals' Wolverine Design Is Certainly a Choice - IGN Daily Fix
NEW YORK (AP) — U.S. stock indexes got back to climbing on Wednesday after the latest update on inflation appeared to clear the way for more help for the economy from the Federal Reserve . The S&P 500 rose 0.8% to break its first two-day losing streak in nearly a month and finished just short of its all-time high. Big Tech stocks led the way, which drove the Nasdaq composite up 1.8% to top the 20,000 level for the first time. The Dow Jones Industrial Average, meanwhile, lagged the market with a dip of 99 points, or 0.2%. Stocks got a boost as expectations built that Wednesday’s inflation data will allow the Fed to deliver another cut to interest rates at its meeting next week. Traders are betting on a nearly 99% probability of that, according to data from CME Group, up from 89% a day before. If they’re correct, it would be a third straight cut by the Fed after it began lowering rates in September from a two-decade high. It’s hoping to support a slowing job market after getting inflation nearly all the way down to its 2% target. Lower rates would give a boost to the economy and to prices for investments, but they could also provide more fuel for inflation. “The data have given the Fed the ‘all clear’ for next week, and today’s inflation data keep a January cut in active discussion,” according to Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. Expectations for a series of cuts to rates by the Fed have been one of the main reasons the S&P 500 has set an all-time high 57 times this year , with the latest coming last week. The biggest boosts for the index on Wednesday came from Nvidia and other Big Tech stocks. Their massive growth has made them Wall Street’s biggest stars for years, though other kinds of stocks have recently been catching up somewhat amid hopes for the broader U.S. economy. Tesla jumped 5.9% to finish above $420 at $424.77. It’s a level that Elon Musk made famous in a 2018 tweet when he said he had secured funding to take Tesla private at $420 per share . Stitch Fix soared 44.3% after the company that sends clothes to your door reported a smaller loss for the latest quarter than analysts expected. It also gave financial forecasts for the current quarter that were better than expected, including for revenue. GE Vernova rallied 5% for one of the biggest gains in the S&P 500. The energy company that spun out of General Electric said it would pay a 25 cent dividend every three months, and it approved a plan to send up to another $6 billion to its shareholders by buying back its own stock. On the losing end of Wall Street, Dave & Buster’s Entertainment tumbled 20.1% after reporting a worse loss for the latest quarter than expected. It also said CEO Chris Morris has resigned, and the board has been working with an executive-search firm for the last few months to find its next permanent leader. Albertsons fell 1.5% after filing a lawsuit against Kroger, saying it didn’t do enough for their proposed $24.6 billion merger agreement to win regulatory clearance. Albertsons said it’s seeking billions of dollars in damages from Kroger, whose stock rose 1%. A day earlier, judges in separate cases in Oregon and Washington nixed the supermarket giants’ merger. The grocers contended a combination could have helped them compete with big retailers like Walmart, Costco and Amazon, but critics said it would hurt competition. After terminating the merger agreement with Kroger, Albertsons said it plans to boost its dividend 25% and increased the size of its program to buy back its own stock. Macy’s slipped 0.8% after cutting some of its financial forecasts for the full year of 2024, including for how much profit it expects to make off each $1 of revenue. All told, the S&P 500 rose 49.28 points to 6,084.19. The Dow dipped 99.27 to 44,148.56, and the Nasdaq composite rallied 347.65 to 20,034.89. In the bond market, the yield on the 10-year Treasury rose to 4.27% from 4.23% late Tuesday. The two-year Treasury yield, which more closely tracks expectations for the Fed, edged up to 4.15% from 4.14%. In stock markets abroad, indexes rose across much of Europe and Asia. Hong Kong’s Hang Seng was an outlier and slipped 0.8% as Chinese leaders convened an annual planning meeting in Beijing that is expected to set economic policies and growth targets for the coming year. South Korea’s Kospi rose 1%, up for a second straight day as it climbs back following last week’s political turmoil where its president briefly declared martial law. AP Writers Matt Ott and Zimo Zhong contributed.
NoneCanadians face a fresh wave of scams as fraudsters seize on the Canada Post strike to try to trick victims out of their cash. The last few weeks have seen an “exponential” rise in attempted fraud, ranging from phishing emails to deepfake phone calls, says Octavia Howell, chief information security officer at Equifax Canada. “Any time there is a major political event, a major strike or anything like that, we’ll see an uptick,” she said in a phone interview. “Not only is there a Canada post strike ... it’s the holidays.” Scams related to parcels and deliveries typically tick up in step with online shopping orders this time of year, but the work stoppage at Canada Post has led to even more fraud attempts amid the confusion around shipments, Howell said. Comprehensive figures on the latest batch of scams are not yet available from Equifax Canada, but the credit bureau’s daily updates have marked the rise nonetheless. Rather than the roughly half-dozen daily consumer fraud reports of previous increases, Equifax Canada’s investigations team is filing up to “87 in one report in one day coming from the same IP addresses,” said Howell. She called the trend “insidious.” “We’re seeing exponential growth in the amount of scams that are actually happening ... because, one, holidays, and then two, people aren’t able to get their shipments out.” Mail carriers walked off the job on Nov. 15, halting deliveries of letters and packages at the start of the holiday shipping season. Canada Post cautions users that it never reaches out about a delivery via text or e-mail unless it has been requested to. The Crown corporation has asked Canadians to be on guard for telltale signs of a phishing scam or fraud attempt, including poor grammar, imagery inconsistent with Canada Post logos and a tracking number at odds with its standard format. The Better Business Bureau similarly cautioned users when the strike kicked off. “Watch out for fake package delivery offers during Canada’s postal strike,” the non-profit said in a release last month. It advised potential victims to verify delivery services, avoid unsolicited shipment offers from little-known companies and check for accreditation by the bureau before selecting a service. It also noted that scammers may send false messages claiming to be from Canada Post or another carrier asking for payment for undelivered items or offering “priority service.” “Do not click on links in unsolicited emails or texts. Instead, visit the official website of the courier service for updates,” the bureau said. Canada Post recommends customers contact the Canadian Anti-Fraud Centre if they receive a suspicious e-mail, text or call related to the postal service.
2 House Republicans seek to stop IVF expansion in defense bill
HOUSTON , Dec. 2, 2024 /PRNewswire/ -- OptiSigns, a leader in digital signage software solutions, is thrilled to announce its participation as a Platinum Sponsor in this year's Digital Signage Experience (DSE) 2024, taking place this December in Las Vegas, Nevada . The highly anticipated event, a premier gathering for digital signage innovators, professionals, and enthusiasts, will provide the perfect stage for OptiSigns to unveil its latest advancements and engage with industry leaders. Visitors of DSE 2024 will have the opportunity to experience firsthand how OptiSigns' powerful and user-friendly platform is transforming how businesses communicate, engage, and inform their audiences. From dynamic content scheduling to seamless integrations and real-time updates, OptiSigns' solutions are designed to meet the needs of businesses across industries, including retail, hospitality, healthcare, and more. "At OptiSigns, we are passionate about empowering businesses with technology that engages audiences and drives results," said Head of Sales John Shelley. "We are excited to connect with industry professionals at DSE 2024, showcase our solutions, and demonstrate how digital signage can transform communication strategies." DSE 2024 will take place from December 9, 2024 , to December 10, 2024 , at the Las Vegas Convention Center in Las Vegas, Nevada , and promises to bring together key players and thought leaders in digital signage, offering a unique platform to explore the latest technologies and network with industry professionals. What to Expect from OptiSigns at DSE 2024: Live Demonstrations: Visitors of DSE can visit OptiSigns booth #3134 to explore the intuitive features of the OptiSigns platform and learn how it can simplify and enhance digital signage management. Using OptiSigns innovative technology like the Pro Player and Android Stick, visitors will be treated to LIVE Demos of unique OptiSigns features like Audience Intelligence, the OptiSync Data Management System, and the Lift and Learn Interactive Kiosk Experience. New Product Announcements: Stop by OptiSigns booth #3134 and be the first to see the newest innovative Pro Max technology designed by OptiSigns and learn more about unique updates that will redefine the digital signage landscape. Our newest Pro Max technology is our most powerful digital signage player that supports 8K or 4x4K video walls. With OptiSigns experts onsite, visitors will have the opportunity to discuss trends, best practices, and strategies for maximizing the impact of digital signage. Exclusive Giveaways and Promotions: Attendees visiting OptiSigns booth #3134 will have access to special offers, giveaways, and prizes. This year, OptiSigns will unleash their interactive Opti Claw Machine, tantalizing visitors with a chance to win OptiSigns Android Sticks, Pro Players, Optibot Keychains, and more. One lucky winner will win a brand new PS5 Pro via a LinkedIn competition, and the winner will be announced LIVE at DSE! For more information on the PS5 giveaway, check out OptiSigns' LinkedIn page. About OptiSigns OptiSigns is a leading digital signage software provider dedicated to helping businesses create engaging, impactful content experiences. Focusing on simplicity, scalability, and innovation, OptiSigns empowers organizations to communicate their message effectively and captivate their audience through digital displays. For more information on OptiSigns, visit www.optisigns.com or follow us on all social media @OptiSignsInc. Media Contact: Aisha Albritton Director of Trade Show Strategy and Event Marketing Aisha.Albritton@OptiSigns.com | (404) 641-0613 View original content to download multimedia: https://www.prnewswire.com/news-releases/optisigns-to-showcase-cutting-edge-digital-signage-solutions-at-the-digital-signage-experience-2024-in-las-vegas-302320107.html SOURCE OptiSigns
NoneOWINGS MILLS, Md. -- Baltimore Ravens coach John Harbaugh was vague on the future of recently acquired Diontae Johnson , a day after the wide receiver didn't play a snap in Sunday's 24-19 loss to the Philadelphia Eagles . "At this time, I'm going to have to wait just to clarify it," Harbaugh said Monday. "There's some moving parts there that we're going to have to figure out and explore and just see where we're at. I know that's not the answer you want, but that's the best I can do in fairness to everybody right now." In four games with the Ravens, Johnson has one catch for six yards. He suited up Sunday but didn't play, even after starting wide receiver Rashod Bateman left the game in the third quarter with a knee injury. Harbaugh was noncommittal on whether Johnson will remain with the team. "We'll just work it out [and] see where we're at over the next few days this week," said Harbaugh, whose team is on a bye this week. Editor's Picks Ravens back Tucker after kicking woes continue 19h Jamison Hensley Johnson, 28, led the Carolina Panthers in receptions (30), receiving yards (357) and touchdown catches (three) through the first seven games before being dealt to Baltimore on Oct. 29. The Ravens sent a fifth-round pick to Carolina for Johnson and a sixth-round selection. It was considered a low-risk move because the Panthers picked up most of Johnson's remaining salary, leaving Baltimore to pay about $625,000. In Johnson's first game with the Ravens on Nov. 7, he caught his only pass for Baltimore while playing five snaps. Over his next three games, Johnson was targeted three times with no receptions while participating in a total of 17 snaps. After Sunday's game, quarterback Lamar Jackson said he spoke to Johnson about staying locked in after not playing. "We want him out there," Jackson said. "He's a great receiver. We didn't get him from the Panthers for nothing." A third-round pick in 2019 by the Steelers , Johnson has totaled 422 catches for 4,726 yards and 28 touchdowns for Pittsburgh, Carolina and Baltimore. Jackson's top three receivers are Zay Flowers , Bateman and Nelson Agholor . Harbaugh said Bateman's knee injury is not a long-term one.
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the first patient has been dosed in Jasper's Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN ( E valuating T he E fficacy and S afety of briquilimab I n particip AN ts with allergic asthma). The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma. "Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast cell activity,” said Edwin Tucker, M.D., Chief Medical Officer of Jasper. "Following dose escalation through Part 2 of the BEACON study in CSU, we obtained regulatory clearance to move directly to a subcutaneous 180mg dose in the ETESIAN study, which we believe will drive deep mast cell depletion in the airways and enable durable clinical benefit for patients with asthma. We look forward to providing enrollment updates as we progress through the study and anticipate reporting the initial data in the second half of 2025.” The Phase 1b/2a ETESIAN study is a single dose double-blind, placebo-controlled challenge study that is expected to enroll approximately 30 patients across as many as 7 sites in Canada with a key objective of demonstrating proof-of-concept in asthma utilizing a potential therapeutic dose to inform future trials in the broader asthma population. The study will be conducted utilizing a single 180mg dose of subcutaneous briquilimab and key assessments will include both early and late asthmatic response, changes in airway hyperresponsiveness, mast cell depletion and recovery, and safety. "Depletion of mast cells via inhibition of c-Kit is a novel mechanism with the potential to alleviate asthmatic response in patients underserved by existing therapies,” said Paul O'Byrne, M.D., Professor, Dean and Vice President of the Faculty of Health Sciences at McMaster University. "As a potent and targeted c-Kit inhibitor, I believe briquilimab has the potential to overcome the safety issues that have limited development of other c-Kit inhibiting agents and, in turn, serve as an important treatment option for patients suffering from asthma. I look forward to enrolling patients into the ETESIAN study.” About Briquilimab Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and allergic asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU, and as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), Fanconi anemia (FA), and sickle cell disease (SCD). About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and asthma. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU and as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertx.com . Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe,” "may,” "will,” "estimate,” "continue,” "anticipate,” "intend,” "expect,” "should,” "would,” "plan,” "predict,” "potential,” "seem,” "seek,” "future,” "outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma, the potential for deep mast cell depletion in the airways and its potential ability to enable durable clinical benefit for patients with asthma; Jasper's expectations regarding the Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, including protocols, expected patient enrollment, expected site locations, expected key objective and key assessments and expected timing to report initial data; and Jasper's expectations regarding building out its pipeline of programs evaluating briquilimab in mast cell driven diseases. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 [email protected] Joyce Allaire (investors) LifeSci Advisors 617-435-6602 [email protected] Lauren Walker (media) Real Chemistry 646-564-2156 [email protected]Marvel Rivals' Wolverine Design Is Certainly a Choice - IGN Daily Fix